生物技术公司Century Therapeutics, Inc.宣布,其核心研发项目CNTY-813的新药临床试验申请(IND)预计将于2026年第四季度正式提交。若进展顺利,该项目首批临床数据有望在2027年下半年对外披露。
CNTY-813作为公司创新细胞疗法管线的重要组成,其研发进展备受市场关注。此次明确的时间节点为投资者提供了可预期的研发里程碑,也反映出公司对项目推进的精准把控。
生物技术公司Century Therapeutics, Inc.宣布,其核心研发项目CNTY-813的新药临床试验申请(IND)预计将于2026年第四季度正式提交。若进展顺利,该项目首批临床数据有望在2027年下半年对外披露。
CNTY-813作为公司创新细胞疗法管线的重要组成,其研发进展备受市场关注。此次明确的时间节点为投资者提供了可预期的研发里程碑,也反映出公司对项目推进的精准把控。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.